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ABSTRACT The innate immune system protects cells against viral pathogens in part
through the autocrine and paracrine actions of alpha/beta interferon (IFN-/) (type
I), IFN- (type II), and IFN- (type III). The transcription factor interferon regulatory
factor 1 (IRF-1) has a demonstrated role in shaping innate and adaptive antiviral im-
munity by inducing the expression of IFN-stimulated genes (ISGs) and mediating sig-
nals downstream of IFN-. Although ectopic expression experiments have suggested
an inhibitory function of IRF-1 against infection of alphaviruses in cell culture, its
role in vivo remains unknown. Here, we infected Irf1/ mice with two distantly re-
lated arthritogenic alphaviruses, chikungunya virus (CHIKV) and Ross River virus
(RRV), and assessed the early antiviral functions of IRF-1 prior to induction of adap-
tive B and T cell responses. IRF-1 expression limited CHIKV-induced foot swelling in
joint-associated tissues and prevented dissemination of CHIKV and RRV at early time
points. Virological and histological analyses revealed greater infection of muscle tis-
sues in Irf1/ mice than in wild-type mice. The antiviral actions of IRF-1 appeared
to be independent of the induction of type I IFN or the effects of type II and III IFNs
but were associated with altered local proinﬂammatory cytokine and chemokine re-
sponses and differential inﬁltration of myeloid cell subsets. Collectively, our in vivo
experiments suggest that IRF-1 restricts CHIKV and RRV infection in stromal cells, es-
pecially muscle cells, and that this controls local inﬂammation and joint-associated
swelling.
IMPORTANCE Interferon regulatory factor 1 (IRF-1) is a transcription factor that reg-
ulates the expression of a broad range of antiviral host defense genes. In this study,
using Irf1/ mice, we investigated the role of IRF-1 in modulating pathogenesis of
two related arthritogenic alphaviruses, chikungunya virus and Ross River virus. Our
studies show that IRF-1 controlled alphavirus replication and swelling in joint-
associated tissues within days of infection. Detailed histopathological and virological
analyses revealed that IRF-1 preferentially restricted CHIKV infection in cells of non-
hematopoietic lineage, including muscle cells. The antiviral actions of IRF-1 resulted
in decreased local inﬂammatory responses in joint-associated tissues, which pre-
vented immunopathology.
KEYWORDS interferon, interferon regulatory factor 1, interferon-stimulated genes,
alphavirus, chikungunya virus, Ross River virus
Chikungunya virus (CHIKV) is transmitted to humans primarily by Aedes aegypti andAedes albopictus mosquitoes and causes a debilitating infection characterized by
fever, rash, myositis, and arthritis, with joint disease lasting for months to years in some
individuals (1). While CHIKV historically caused outbreaks that were restricted to parts
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of Africa and Asia, an epidemic occurred in La Réunion island in 2006 (2), with
subsequent spread to millions of individuals in the Indian subcontinent (3). In 2013,
transmission of CHIKV occurred in the Western Hemisphere, and in 18 months, CHIKV
caused more than 1.8 million cases in the Americas in more than 40 countries (4). In
comparison, other arthritogenic alphaviruses (e.g., Ross River virus [RRV], Semliki Forest
virus [SFV], Mayaro virus [MAYV], and Sindbis virus [SINV]) circulate with more limited
global distributions.
The rapid production of interferons (IFNs) in response to a viral infection serves as
a key defense mechanism in vertebrate animals (5, 6). Detection of virus occurs through
the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recog-
nition receptors (PRRs), including Toll-like receptors (TLRs) and retinoic acid inducible
gene 1 (RIG-I)-like receptors (RLRs). PRR engagement of single- and double-stranded
viral RNA in endosomes or in the cytoplasm prompts a signaling cascade that activates
and promotes nuclear translocation of IFN regulatory factor 3 (IRF-3) and NF-B
transcription factors, which bind promoter elements and induce expression of type I
IFNs (7–9). After binding to their receptors, type I IFNs activate Janus kinase (JAK) and
signal transducer and activator of transcription (STAT) pathways to induce expression
of hundreds of IFN-stimulated genes (ISGs) with antiviral and immunomodulatory
activities (10–13).
STAT1 is an essential shared component of the type I (IFN-/), type II (IFN-), and
type III IFN (IFN-) signaling pathways, and interferon regulatory factor 1 (IRF-1) is
induced by type I and type II IFNs downstream of STAT1 nuclear translocation (10). The
transcription factor IRF-1 originally was identiﬁed as a regulator of IFN- expression,
due to its ability to bind IFN-stimulated regulatory elements (ISREs) present in many
IFN-inducible gene promoters (14–16). IRF-1 also transduces part of the IFN- signal
(reviewed in reference 17), as encephalomyocarditis (EMCV) virus infection in Irf1/
ﬁbroblasts was associated with a decrease in IFN--stimulated genes, and IFN--
induced upregulation of cytokines and chemokines in macrophages required the
transcriptional activity of IRF-1 (17–22).
IRF-1 activates antiviral programs against a diverse range of RNA viruses (23–25) and
is required for inhibition of EMCV, West Nile virus (WNV), and murine norovirus (MNoV)
infection in cultured cells (18, 26, 27). IRF-1 has antiviral activities that are independent
of IFN signaling (28, 29), as its ectopic expression in human STAT1/ ﬁbroblasts
inhibited infection of hepatitis C virus (HCV), yellow fever virus (YFV), WNV, CHIKV,
Venezuelan equine encephalitis virus (VEEV), and human immunodeﬁciency virus (HIV)
(25). Notwithstanding these cell-intrinsic immune activities, IRF-1 has additional func-
tions in shaping cellular immunity. Irf1/ mice exhibited defects in CD8 T cells and
natural killer (NK) cells (30, 31) with TH2 skewing and decreased production of IFN- by
CD4 T cells as a consequence of a dysregulated interleukin-12 (IL-12) response (32).
Whereas IRF-1 restricted WNV infection in vivo as a consequence of direct effects on
viral replication and modulation of cellular immune responses (26), IRF-1 restricted
vesicular stomatitis virus (VSV) replication in neurons in the brain through a type I and
type II IFN-independent mechanism (33).
In this study, we assessed the early in vivo antiviral function of IRF-1 against CHIKV
and RRV prior to the induction of adaptive T cell responses. Irf1/ mice inoculated
with CHIKV developed greater acute inﬂammation in joint-associated tissues and higher
viral tissue burden at distant sites within days of infection despite having an apparently
intact type I and II IFN response. Bone marrow chimera experiments and detailed
immunohistochemical analysis suggest a key antiviral and anti-inﬂammatory role for
IRF-1 in radioresistant stromal cells, including muscle cells.
RESULTS
IRF-1 controls alphavirus infection in vivo. To determine whether a genetic
deﬁciency of IRF-1 affected alphavirus pathogenesis, we inoculated 4- to 5-week-old
wild-type (WT) and congenic Irf1/ C57BL/6 mice via a subcutaneous route in the
footpad with 103 focus-forming units (FFU) of a pathogenic CHIKV (La Réunion 2006)
Nair et al. Journal of Virology
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strain and monitored foot swelling for 21 days. Compared to their WT counterparts,
Irf1/ mice were more susceptible to CHIKV-induced ipsilateral foot swelling at early
(e.g., day 3) and later (e.g., day 7) time points (Fig. 1A). To begin to determine the basis
for these clinical phenotypes, we measured the levels of infectious CHIKV in the
joint-associated tissues, sera, and spleens of WT and Irf1/mice. At 12 h postinfection,
no differences in viral titers were detected in any of the tissues of WT and Irf1/ mice.
Whereas the ipsilateral feet of both WT and Irf1/ mice had similar viral burdens up
to 72 h after infection, greater infection was detected in Irf1/ mice in the contralat-
eral feet (61-fold, P  0.05) and serum (9-fold, P  0.02) at 24 h and in the
contralateral feet (19-fold, P  0.02), serum (7-fold, P  0.05), and spleen (17-fold, P 
0.02) at 72 h after infection (Fig. 1B). These experiments suggest that a deﬁciency of
IRF-1 does not substantially impact CHIKV replication at the site of inoculation but
instead restricts spread at early times after inoculation.
Antiviral responses of IRF-1 and type I, type II, and type III IFNs. Since IRF-1
regulates the transcription of IFN- and ISGs in vitro (25, 34), we assessed its impact on
their mRNA levels in joint-associated tissues at 12 and 24 h after inoculation with CHIKV.
Unexpectedly, we observed no substantive difference in expression of Ifn, Ifn1, Ifn4,
Ifn13, Ifn14, Rsad2 (viperin), Iﬁt1, or Iﬁt2 mRNA in Irf1/ and WT mice (Fig. 2A). Thus,
the increased susceptibility of Irf1/ mice to CHIKV did not appear to be due to a
defect of type I IFN induction or signaling. A previous study reported a role for IRF-1 in
the induction of IFN- expression after RLR signaling in peroxisomes (35). To test
whether the increased foot swelling of Irf1/ mice might be due to an absence of
IFN- in vivo, we inoculated IFN- receptor knockout mice (Ifnlr1/) with CHIKV. As no
signiﬁcant difference in foot swelling was observed between WT and Ifnlr1/ mice
(Fig. 2B), the effect of IRF-1 likely is not attributable to a loss of type III IFN signaling.
Since IRF-1 is induced by IFN- and mediates some of its antiviral effects (10), we
next assessed whether the early inhibitory activity of IRF-1 against CHIKV was regulated
by IFN-. Consistent with results of a prior study (36), we observed no differences in
foot swelling and viral burden between WT and IfngR/ mice at day 3 after infection
(Fig. 2C and D). As an independent test, we inhibited IFN- function in both WT and
Irf1/ mice using H22, a blocking monoclonal antibody (MAb) (37). Whereas the
isotype control-treated Irf1/ mice had greater foot swelling and viral burden than
their WT counterparts, as expected, we observed no effect of the IFN--blocking MAb
in WT or Irf1/mice at day 3 after infection (Fig. 2E and F). These experiments suggest
that IRF-1-mediated antiviral effects against CHIKV occur independently of IFN- re-
sponses.
FIG 1 IRF-1 restricts arthritogenic alphaviruses in vivo. Four-week-old WT and Irf1/ mice were inoculated with 103 FFU of CHIKV in the foot. (A)
Swelling of the ipsilateral feet of infected WT (n  10) and Irf1/ (n  15) mice was followed for 21 days after infection. Area was determined
by measuring the width and height of the ankle region of the foot using digital calipers. Error bars represent standard error of the mean (SEM).
Data are pooled from two independent experiments. Asterisks indicate statistical differences (2-way ANOVA with Sidak’s multiple-comparison test:
**, P  0.01; ****, P  0.0001). (B) Viral titers in the ipsilateral (I.) foot, contralateral (C.) foot, serum, and spleen were analyzed at 12, 24, and 72
h after infection. Data are pooled from two or three independent experiments, and each data point represents one mouse. Bars indicate mean
values, and the dotted line represents the limit of detection. Asterisks indicate statistical differences (Mann-Whitney test: *, P  0.05; **, P  0.01;
***, P  0.001).
IRF-1 Restricts CHIKV Infection and Inﬂammation Journal of Virology





ber 8, 2017 by W






IRF-1-dependent antiviral responses against CHIKV preferentially occur in
radioresistant cells. We next evaluated whether the antiviral actions of IRF-1 origi-
nated from the radioresistant stromal cells or radiosensitive hematopoietic cells. We
established reciprocal WT and Irf1/ chimeric mice after sublethal irradiation and
bone marrow reconstitution (Fig. 3A and B). At 6 to 8 weeks after reconstitution,
FIG 2 IRF-1-mediated antiviral responses against CHIKV are independent of IFN-/, IFN-, and IFN-. Four-week-old WT and Irf1/ mice were
inoculated with 103 FFU of CHIKV in the ipsilateral foot. (A) Ipsilateral (I.) foot joint-associated tissues were assayed for IFN-, IFN-1, IFN-4,
IFN-13, IFN-14, and ISGs (Isg15, Rsad2, Iﬁt1, and Iﬁt2) mRNAs by qRT-PCR. Bars indicate mean values, with each point representing one mouse
from experiments performed in duplicate. Data are pooled from two independent experiments. (B) Four-week-old WT and Ifnlr1/ mice were
inoculated with 103 FFU of CHIKV in the foot. Swelling of the ipsilateral feet of infected WT (n  10) and Ifnlr1/ (n  9) mice was followed for
12 days. Area was determined by measuring the width and height of the ankle using digital calipers. Data are pooled from two independent
experiments. Error bars indicate SEM. No statistical differences were found by 2-way ANOVA with Sidak’s multiple-comparison test. (C)
Four-week-old WT and IfngR/ mice were inoculated with 103 FFU of CHIKV in the foot. Swelling of the ipsilateral feet of infected WT (n  11)
and IfngR/ (n  9) mice were measured at day 2 and day 3 after infection. Error bars indicate the SEM. No statistical differences were found
using a 2-way ANOVA with Sidak’s multiple-comparison test. (D) Viral titers in the ipsilateral (I.) and contralateral (C.) feet were analyzed at day
3 after infection. Data are pooled from two independent experiments, and each point represents one mouse. Bars represents means, and the
dotted line represents the limit of detection. No statistical difference was measured (Mann-Whitney test). (E and F) Four-week-old WT and Irf1/
mice were treated with isotype control (PIP) or IFN--blocking (H22) MAbs as indicated. (E) Swelling of the ipsilateral feet of CHIKV-infected isotype
control MAb-treated WT and Irf1/ mice (WT, days 2 and 3 [n  9]; Irf1/, day 2 [n  8] and day 3 [n  7]) or anti-IFN--treated mice (WT, days
2 and 3 [n  9]; Irf1/, days 2 and 3 [n  7]) was measured. Data are pooled from two independent experiments. Asterisks indicate statistical
differences (2-way ANOVA with Sidak’s multiple-comparison test: *, P  0.05; **, P  0.01; ***, P  0.001). (F) Viral titers in the ipsilateral and
contralateral feet of isotype- and anti-IFN- MAb-treated mice were analyzed at day 3 after infection. Data are pooled from two independent
experiments, and each point represents one mouse. Bars represent mean values, and the dotted line represents the limit of detection. Asterisks
indicate statistical differences (Mann-Whitney test: **, P  0.01; ***, P  0.001).
Nair et al. Journal of Virology
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chimeric mice were inoculated with CHIKV and monitored for foot swelling and viral
infection. Irf1/¡ WT chimeras sustained foot swelling that was comparable to that
of WT ¡ WT mice (Fig. 3C). In contrast, WT ¡ Irf1/ chimeras had the same clinical
phenotype of increased foot swelling after CHIKV infection as Irf1/¡ Irf1/ chime-
ras. Virological analysis revealed that while all four groups exhibited similar titers in the
ipsilateral feet, higher CHIKV infection was observed in the contralateral feet of WT ¡
Irf1/ and Irf1/¡ Irf1/ mice than in those of Irf1/¡ WT and WT¡ WT mice
(Fig. 3D). These data suggest that the antiviral effects of IRF-1 at early times after CHIKV
inoculation occur largely in the radioresistant cells, and this mitigates joint-associated
swelling.
Early IRF-1-dependent antiviral responses restrict CHIKV infection in muscle
cells. To deﬁne the stromal cell type in which IRF-1 mediated its antiviral effects, we
performed in situ hybridization and immunohistochemistry for viral RNA and antigen in
the ipsilateral foot at day 3 after CHIKV infection of WT and Irf1/ mice. CHIKV RNA
staining in joint-associated tissues from WT and Irf1/ mice was apparent in muscle
cells and synovial ﬁbroblasts (Fig. 4A). Corresponding hematoxylin and eosin (H&E)
staining did not reveal substantive differences in leukocyte inﬁltration of WT and
Irf1/ joint-associated tissues at this early time point (Fig. 4B). To further assess
differences in infection of WT and Irf1/ muscle cells and ﬁbroblasts, we costained
tissue sections for CHIKV E2 antigen, skeletal muscle sarcomeric -actinin (SAA), and
ﬁbroblast vimentin proteins. Although infected muscle cells and ﬁbroblasts were
apparent in both the ipsilateral and contralateral feet of WT and Irf1/ mice, albeit at
lower levels in the contralateral feet, we observed greater numbers of infected SAA-
positive muscle cells but not vimentin-positive ﬁbroblasts in Irf1/ animals (Fig. 5A to
C, E, and G to J). Correspondingly, higher viral titers were detected in the ipsilateral and
FIG 3 IRF-1 expression in radioresistant cells restricts CHIKV infection. (A) Four-week-old CD45.1 B6.SJL and CD45.2 Irf1/mice were irradiated
and reconstituted with CD45.1 B6.SJL or CD45.2 Irf1/ bone marrow (107 cells/mouse). (B) Representative ﬂow cytometry plots of CD45.1 cells
in Irf1/ mice and CD45.2 cells in CD45.1 B6.SJL mice at 6 weeks after reconstitution. (C and D) Ten-week-old chimeric mice were inoculated
with 103 FFU of CHIKV in the foot. (C) Swelling of the ipsilateral feet of chimeric mice WT (CD45.1) and Irf1/mice (WT¡WT, n 7; Irf1/¡ Irf1/,
n  8; WT¡ Irf1/, n  8; Irf1/¡ WT, n  10) was measured at days 0, 2, and 3 days after infection. Data are pooled from two independent
experiments. Asterisks indicate statistical differences (Mann Whitney test: **, P  0.01; ***, P  0.001; ****, P  0.0001), and error bars represent
SEM. (D) Viral titers in the ipsilateral and contralateral feet of chimeric mice were analyzed at days 2 and 3 after infection. Data are pooled from
two independent experiments, and each point represents one mouse. Bars represent mean values, and the dotted line represents the limit of
detection. Asterisks indicate statistical differences (Mann Whitney test: ***, P  0.001; ****, P  0.0001).
IRF-1 Restricts CHIKV Infection and Inﬂammation Journal of Virology
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contralateral gastrocnemius muscles from Irf1/ mice than in those from WT mice at
24 and 72 h after infection (Fig. 5D and F). These data suggest that IRF-1-dependent
antiviral responses preferentially restrict CHIKV replication in skeletal muscle cells
during the early stages of infection.
Impact of IRF-1 on inﬂammatory responses. To determine whether the enhanced
swelling observed in the extremities of CHIKV-infected Irf1/ mice at day 3 was due
to an altered inﬂammatory response, we determined the composition of the cell
inﬁltrates using ﬂow cytometry (Fig. 6A). Consistent with the histological analysis of
tissue sections (Fig. 4B), the total numbers of CD45 leukocytes in the feet were similar
for WT and Irf1/ mice at day 3 after infection. However, an analysis of immune cell
types revealed that CHIKV-infected Irf1/ mice had greater inﬁltration of granulocytes
(CD11b Ly6Ghi Ly6Cmid neutrophils [5.4-fold, P  0.0001] and CD11b SiglecF
eosinophils [3.2-fold, P  0.005]) but fewer CD11b Ly6Chi inﬂammatory monocytes
(1.6-fold, P  0.05) in their ipsilateral feet than WT mice (Fig. 6A). Given the differences
in myeloid cell trafﬁcking patterns, we measured a panel of 24 cytokines and chemo-
kines in the soft tissues of the ipsilateral foot at day 3. We detected higher expression
of IL-4, IL-6, CXCL1, CXCL2, CCL3, and CCL4 in CHIKV-infected Irf1/ mice than in WT
FIG 4 Loss of IRF-1 expression results in increased CHIKV infection in skeletal muscle. Four-week-old WT and Irf1/ mice were inoculated with
103 FFU of CHIKV in the ipsilateral footpad, and tissues were processed on day 3 after infection. (A) In situ hybridization for CHIKV RNA with Gill’s
hematoxylin staining on naive WT and infected WT and Irf1/ joint-associated tissues from the foot. Arrows on the 100 images indicate CHIKV
RNA (brown staining) in muscle and ﬁbroblast cells. Cell types were distinguished by morphology. (B) Hematoxylin and eosin staining of
CHIKV-infected WT and Irf1/ joint-associated tissues. Scale bars at magniﬁcation: 0.87  2.5 mm, 20  100 m, and 100  10 m. The
0.87 and 20 images were acquired on a Hamamatsu NanoZoomer 2.0-HT system. The 100 images were acquired on a Zeiss Axio Obesrver.D1
Wideﬁeld ﬂuorescence microscope. Data are representative of at least two independent experiments with two mice per experiment.
Nair et al. Journal of Virology
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FIG 5 Loss of IRF-1 expression results in increased CHIKV antigen and infection in skeletal muscle. (A to C, E, and G to J) Confocal microscopy
analysis of ipsilateral (I.) and contralateral (C.) joint-associated tissues at day 3 after CHIKV inoculation of WT and Irf1/ mice. The sections were
stained for CHIKV E2 antigen using anti-CHIKV MAbs (CHK-152 and CHK-166). The sections were counterstained with DAPI and costained with
anti-sarcomeric -actinin (SAA) (A and B) or anti-vimentin (G and H). Scale bars, 50 m. CHIKV antigen colocalization in SAA-positive muscle cells
of ipsilateral (C) and contralateral (E) feet or in vimentin-positive ﬁbroblasts of ipsilateral (I) and contralateral (J) feet was quantiﬁed using Image
J software. Data are pooled from two or three independent experiments with 1 or 2 mice in each experiment (2 to 4 sections per mouse). Bars
represent mean values, and each data point represents the percentage of colocalization from each quantiﬁed image. Asterisks indicate statistical
signiﬁcance (Mann Whitney test: **, P  0.01). (D and F) Viral titers in the ipsilateral (I.) (D) and contralateral (C.) (F) gastrocnemius muscles at 12,
24, and 72 h after infection. Data are pooled from three independent experiments, and each point represents one mouse. Bars indicate mean
values, and the dotted line represents the limit of detection. Asterisks indicate statistical differences (Mann-Whitney test: *, P  0.05; **, P  0.01;
***, P  0.001)
.
IRF-1 Restricts CHIKV Infection and Inﬂammation Journal of Virology
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mice (Fig. 6B). However, no signiﬁcant differences in levels of cytokines IL-1, IL-1,
IL-12p40, IL-12p70, IL-17, tumor necrosis factor alpha (TNF-), and IFN- and chemo-
kines CCL2, CCL5, and CCL11 were observed between WT and Irf1/ mice. (Fig. 2A).
The remaining eight cytokines (IL-2, IL-3, IL-5, IL-9, IL-10, IL-13, IL-17A, and granulocyte-
macrophage colony-stimulating factor [GM-CSF]) were below the level of detection at
day 3 after infection. The increased expression of granulocyte-attracting chemokines
(e.g., CXCL1, CXCL2, and CCL3) in joint-associated tissues from Irf1/mice may explain
the greater inﬂux of neutrophils and eosinophils after CHIKV infection. Thus, IRF-1
expression in joint-associated tissues early during infection regulates the local inﬂam-
matory responses, possibly because of its ability to control CHIKV replication in speciﬁc
cell types.
Early IRF-1-dependent antiviral responses also restrict RRV infection. To test
whether the antiviral effect of IRF-1 could affect replication of another arthritogenic
alphavirus, we inoculated WT and Irf1/ mice via a subcutaneous route with RRV and
evaluated the viral burden in the ipsilateral foot and at distant sites. Immunohisto-
chemical analysis revealed greater numbers of RRV-infected muscle cells in Irf1/ than
FIG 6 Loss of IRF-1 results alters inﬂammatory responses in infected tissue. (A) Representative ﬂow cytometry plots for neutrophils (CD11c
CD11b Ly6Ghi Ly6Cmid), inﬂammatory monocytes (CD11c CD11b Ly6G Ly6Chi), and macrophages (CD11c CD11b Ly6G Ly6C) in the
ipsilateral feet of CHIKV-infected WT mice at day 3 after infection (left) and numbers of immune cells subsets in the ipsilateral feet of
CHIKV-infected WT and Irf1/ mice (right). Data are pooled from three independent experiments, with each dot representing an individual
mouse. Bars indicate mean values, and asterisks denote statistical differences (Mann-Whitney test: *, P  0.05; **, P  0.01; ****, P  0.0001; ns,
not signiﬁcant). (B) The joint-associated tissues from the ipsilateral feet were harvested at day 3 and analyzed for proinﬂammatory cytokines and
chemokines. Bars indicate mean values, dotted lines represent the limit of detection, and each point represents one mouse. Values below the limit
of detection were plotted at the limit of detection. Data are pooled from two independent experiments. Asterisks indicate statistical differences
(Mann-Whitney test: *, P  0.05; **, P  0.01; ns, not signiﬁcant).
Nair et al. Journal of Virology
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in WT mice (Fig. 7A to D). Since RRV infection does not cause clinical signs in mice
within the ﬁrst 4 days of infection (38), we measured viral titers at day 3. Higher RRV
titers were measured in the ipsilateral (4-fold, P  0.002) and contralateral (8-fold, P 
0.002) feet, ipsilateral (16-fold, P  0.002) and contralateral (18-fold, P  0.0001)
quadriceps muscles, sera (650-fold, P  0.005), and spleens (4-fold, P  0.05) of Irf1/
than in those of WT mice (Fig. 7C). Thus, IRF-1 has an early antiviral function against
infection by multiple arthritogenic alphaviruses.
DISCUSSION
Although the roles of IRF-3, IRF-7, and IRF-9 in regulating IFN-dependent defense
responses are established, the biological relevance of the transcription factor IRF-1 in
antiviral responses has remained less certain despite its discovery more than 20 years
ago (34). IRF-1-mediated antiviral responses have been reported in vitro against a range
of viruses, including WNV, tick borne encephalitis virus, YFV, HCV, EMCV, MNoV, and
VSV (18, 26, 27, 29, 33, 39, 40). Although in vivo studies in mice have established a
protective role for IRF-1 against WNV, MNoV, and VSV (26, 27, 33), the contribution of
its innate functions has remained less certain. Indeed, in the sole prior study with
Irf1/ mice and an alphavirus (VEEV), only the effects of IRF-1 on vaccine immunity
were explored (41). We evaluated the effects of IRF-1 on the early (day 3 and prior)
antiviral responses against arthritogenic alphaviruses in vivo prior to induction of
adaptive immunity. We identiﬁed IRF-1 as an essential component of the early host
immune response against CHIKV and RRV. Irf1/ mice were more susceptible to
FIG 7 Loss of IRF-1 expression results in increased RRV infection. Four-week-old WT and Irf1/ mice were inoculated with 103 FFU of RRV in the
footpad. (A and B) Confocal microscopy analysis of ipsilateral (I.) feet (A) and ipsilateral gastrocnemius (I.G.) muscles (B) at day 3 after RRV infection
of WT and Irf1/mice. The sections were stained for E2 antigen using anti-RRV MAbs. The sections were counterstained with DAPI and costained
with anti-sarcomeric -actinin (SAA). Scale bars, 50 m. (C and D) Quantiﬁcation of RRV E2 antigen colocalization in SAA-positive muscle cells of
ipsilateral (I.) feet (C) and ipsilateral gastrocnemius (I.G.) muscles (D) from WT and Irf1/ mice. Data are pooled from 3 mice (3 or 4 sections per
mouse). Bars indicate mean values, and each data point represents the percentage of colocalization of RRV antigen in SAA-positive cells from each
image. Asterisks indicate statistical signiﬁcance (Mann-Whitney test: ****, P  0.0001; *, P  0.05). (E) Infectious viral burden was measured in the
ipsilateral (I.) and contralateral (C.) feet, quadriceps muscle, spleen, and serum at day 3 after infection. Data are pooled from two independent
experiments, and each point represents one mouse. Bars indicate mean values, and the dotted line represents the limit of detection Asterisks
indicate statistical differences (Mann-Whitney test: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001).
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infection at early time points, and in the context of CHIKV infection they developed
enhanced musculoskeletal disease characterized by increased foot swelling. As we
assessed the antiviral function of IRF-1 prior to its well-characterized effects on matu-
ration of adaptive T cell responses (26, 32), the effects of IRF-1 on early CHIKV
pathogenesis preferentially reﬂect its innate immune activity.
Type I, II, and III IFNs are mediators of the early innate immune response by virtue
of their ability to induce panoply of ISGs with antiviral and proinﬂammatory activities,
the latter of which shape the cellularity of inﬁltrating immune responses (reviewed in
references 5, 10, 17, 42, 43, 44, and 35). Unexpectedly, type I IFN signaling functions
appeared to be intact in joint-associated tissues in Irf1/mice, as IFN-, IFN-, and ISG
mRNA expression levels were not altered after CHIKV infection compared to those in
WT mice. Thus, the increased swelling and virological phenotypes in CHIKV-infected
Irf1/ mice were not due to altered type I, II, or III IFN signaling pathways. At least in
the context of CHIKV infection, IRF-1-dependent transcriptional signals appear to
activate antiviral effector pathways directly to achieve host-mediated control.
Alphaviruses have evolved strategies to evade cell-intrinsic and -extrinsic innate
host defenses, including host translational shutoff (45), blockade of transcription of
IRF-3-dependent antiviral genes (46), and direct evasion of antiviral ISGs (47). Despite
the many ways that alphaviruses antagonize antiviral defenses, host cells still restrict
their infection. Indeed, IRF-1 can mediate antiviral effects in the absence of IFNs (48) by
binding to conserved elements in the promoters of its target genes. Even in STAT1/
cells, which lack efﬁcient type I, II, or III IFN signaling, ectopic expression of IRF-1
induced more than 100 target genes and inhibited replication of several families of
viruses, including alphaviruses (25, 40). Consistent with these data, ectopic expression
of IRF-1 in cortical neurons inhibited infection of ﬂaviviruses (WNV and St. Louis
encephalitis viruses), alphaviruses (VEEV), and coronaviruses (mouse hepatitis virus)
(49), and in vivo, IRF-1 expression reduced infection by VSV in neurons through a type
I-independent mechanism (33). At present, it remains unknown which IRF-1-induced
genes mediate the antiviral effects against alphaviruses or other unrelated viral families.
Since the epidemic in La Réunion Island of 2006 and its spread to the Western
Hemisphere, the mechanisms of immune-mediated protection and pathogenesis of
CHIKV infection and disease have been studied intensively (50). Experimental infection
of different strains of immunocompetent mice results in an acute and persistent
musculoskeletal disease characterized by infection and inﬂammation of joint-associated
tissues, resulting in myositis, synovitis, and, arthritis (51–54). In terms of the cellular
tropism in musculoskeletal tissues, in mice and nonhuman primates, CHIKV replicates
preferentially in ﬁbroblasts, mesenchymal cells, and osteoblasts (55, 56). CHIKV infec-
tion in humans commonly causes myositis (57); indeed, in the La Réunion island
outbreak 97.7% of individuals reported muscle pain (58), and biopsies of CHIKV-
infected individuals revealed CHIKV antigen in muscle satellite cells (59). In our murine
model of CHIKV infection, IRF-1 expression in radioresistant stromal cells mitigated
infection and swelling of joint-associated tissues. Our virological and immunohisto-
chemical studies suggest that IRF-1-dependent antiviral responses in muscle cells
contribute to restriction of infection in vivo.
Local inﬂammatory responses in joint-associated tissues inﬂuence disease progres-
sion during arthritogenic alphavirus infections (38, 51, 53). Studies in mice have shown
that a dysregulated myeloid cell response promotes joint swelling and immune-
mediated pathology (60, 61). Our studies establish a key role of IRF-1 in preventing
excessive musculoskeletal disease by restricting virus replication in muscle cells and
thus dampening expression of proinﬂammatory cytokines and chemokines. DD264 and
brequinar are broad-spectrum antiviral compounds that have activity against CHIKV
and reportedly function through an IRF-1-dependent cell-intrinsic immune ampliﬁca-
tion (62). As DD264 becomes commercially available, the speciﬁcity of its mechanism of
action can be corroborated in CHIKV-infected WT and Irf1/ mice. Given the reported
toxic effects of brequinar on myeloid cells (63, 64), interpretation of results after in vivo
administration of this drug may be more challenging.
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In summary, our experiments establish that IRF-1 is a key transcription factor in the
host defense response against arthritogenic alphavirus infection. Because IRF-1 can
regulate antiviral genes directly in a cell type-speciﬁc and IFN-independent manner
(40), evaluations of candidate downstream effector genes through clustered regularly
interspaced short palindromic repeat (CRISPR)-Cas9 gene editing are planned. More-
over, when Irf1ﬂ/ﬂ mice become available, conditional gene deletion in muscle cells
and/or ﬁbroblasts in vivo will further delineate the temporal and spatial roles of IRF-1
in regulating alphavirus tropism and inﬂammation in joint-associated tissues. Such
studies might identify genes that can be targeted pharmacologically to minimize
alphavirus infection and disease in key cell types.
MATERIALS AND METHODS
Virus propagation and titration. CHIKV (La Reunion OPY1 p142, 2006) and RRV (T48) were the gifts
of S. Higgs (Kansas State University) and R. Kuhn (Purdue University), respectively; they were produced
from infectious cDNA clones according to established protocols (38, 65) and propagated in C6/36 Aedes
albopictus cells. Vero cells were used for titration in a virus focus-forming assay (FFA) as described
previously (66).
Mouse experiments and tissue preparation. This study was carried out in accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocols were approved by the Institutional Animal Care and Use Committee at the
Washington University School of Medicine (assurance number A3381-01). Virus inoculations were
performed under anesthesia induced and maintained with ketamine hydrochloride and xylazine, and all
efforts were made to minimize animal suffering. All mouse infection studies were performed in an animal
biosafety level 3 (A-BSL3) laboratory.
Wild-type (WT) C57BL/6J (CD45.2, strain 000664) and B6-SJL (CD45.1, strain 002014) mice were
purchased from Jackson Laboratories. Congenic, backcrossed Irf1/ (31, 67), IFNgR/ (42) and Ifnlr1/
(43, 44) mice were obtained from T. Taniguchi (Tokyo, Japan), H. Virgin (St. Louis, MO), and S. Doyle
(Seattle, WA), respectively, and then genotyped and bred in the animal facility of Washington University
School of Medicine. For infection, 4-week-old (unless mentioned otherwise) age-matched male and
female mice were used. Mice were inoculated subcutaneously in the footpad (103 focus-forming units
[FFU] in 10 l) with virus diluted in phosphate-buffered saline (PBS). Foot size and swelling were
measured prior to infection and monitored daily with digital calipers (Fowler, 100 mm digital caliper). To
quantitate viral burden in tissues on speciﬁc days after infection, mice were perfused extensively with
PBS, tissues were harvested and weighed, and virus titers were determined by focus forming assay (FFA)
as described previously (66).
qRT-PCR assay. Mouse organs were homogenized in TRIzol reagent (Invitrogen). Total RNA was
isolated after TRIzol-chloroform extraction, and quantitative reverse transcription-PCR (qRT-PCR) was
performed using the One-Step RT-PCR master mix and a 7500 Fast real-time PCR system (Applied
Biosystems). IFN, Ifn1, Ifn4, Ifn13, Ifn14, Iﬁt2, Iﬁt1, Rsad2, and ISG15 were detected using qRT-PCR
and normalized to Gapdh expression using the following PrimeTime assays (IDT) according to the manufac-
turer’s instructions. IFN, Mm.PT.58.30132453; IFN1, Mm.PT.58.43426930; IFN4, Mm.PT.58.7678281; IFN13,
Mm.PT.58.41423993; IFN14, Mm.PT.58.42242727; Iﬁt1, Mm.PT.58.32674307; Iﬁt2, Mm.PT.58.28800045.g;
Rsad2, mm.PT.58.11280480; Isg15, mm.PT.58.41476392.g; and Gapdh, Mm.PT.39a1.
Cytokine and chemokine analysis. Mice were inoculated subcutaneously with 103 FFU of CHIKV in
the footpad, and the ipsilateral foot was collected at 3 days after infection, homogenized, and analyzed
for cytokines and chemokines using a Bio-Plex Pro mouse cytokine 23-plex assay kit (Bio-Rad) and a
mouse MIP2/CXCL2 Quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems) according
to the manufacturer’s instructions.
IFN- neutralization. Four-week-old WT and Irf1/ mice were inoculated with 103 FFU of CHIKV
and at 1 day postinfection were administered an anti-IFN- blocking monoclonal antibody (MAb H22;
Leinco, I-438) or an IgG isotype control antibody (MAb PIP; Leinco, I-140). Foot swelling and virological
titers were analyzed at day 2 and/or day 3 after infection.
Bone marrow chimeras. Chimeric mice were generated by using modiﬁcations to a published
protocol (68). Brieﬂy, 4-week-old WT and Irf1/ mice were irradiated with 900 Rads and reconstituted
via intravenous injection with 107 bone marrow cells isolated from the tibias and femurs of 4- to
5-week-old Irf1/ (CD45.2) or WT (CD45.1) mice. At 6 to 8 weeks after bone marrow transplantation,
Irf1/ (CD45.2)¡WT (CD45.1) and WT (CD45.1)¡ Irf1/mice were bled to conﬁrm chimerism by ﬂow
cytometry. Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. Foot swelling and viral
burden in joints were monitored.
Flow cytometry. Chimeric mice were bled, and peripheral blood mononuclear cells were collected.
Cells were stained with CD45.1 V500 (BioLegend, 110741) or CD45.2 allophycocyanin (APC) (eBioscience,
56-0454-82) and analyzed on a MACS Quant Analyzer10 ﬂow cytometer (Miltenyi). Flow cytometry also
was performed on joint-associated tissues from WT and Irf1/ mice at day 3 after CHIKV infection. After
extensive cardiac perfusion, the ipsilateral feet were skinned and disjointed from the tibia. The feet were
digested with collagenase-DNase I solution (2.5 mg/ml collagenase [Sigma, C-0130] and DNase I [Sigma,
D5025] in RPMI with 10% fetal bovine serum [FBS] [HyClone]) for 2 h at 37°C with constant agitation. Cells
were separated by centrifugation and stained with antibodies to CD45 AF700 (BioLegend, 103128),
CD11c APC-Cy7 (BioLegend, 117324), SiglecF phycoerythrin (PE) (BD, 552128), Ly6G PE-Cy7 (BioLegend,
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127618), Ly6C Paciﬁc Blue (BioLegend, 128014), CD3 Paciﬁc Blue (BioLegend, 100214), CD4 APC (Bio-
Legend, 100516), CD8 PE-Cy7 (BioLegend, 100722), B220 V500 (BioLegend, 103227), NK1.1 ﬂuorescein
isothiocyanate (FITC) (BioLegend, 108706), c-kit APC (BioLegend, 105812), and CD11b peridinin chloro-
phyll protein (PerCP)-Cy5.5 (BioLegend, 101228). Cells were analyzed by multicolor ﬂow cytometry on a
BD Fortessa. All data were processed using FlowJo software (FlowJo, LLC).
Immunohistochemistry. Immunohistochemical staining was performed on CHIKV- or RRV-infected
WT and Irf1/ mice at 3 days after infection. After extensive cardiac perfusion with PBS followed by 4%
paraformaldehyde (PFA), the ipsilateral and contralateral feet and gastrocnemius muscle were collected
and ﬁxed for 24 h in 4% PFA. Some of the ﬁxed tissues were decalciﬁed (with 14% EDTA titrated to pH
7.2 with ammonium hydroxide) for 5 to 7 days. Tissues then were washed in PBS, incubated in 30%
sucrose in 0.1 M phosphate buffer for an additional 24 h, and frozen in Tissue Tek compound (Sakura,
4583) at 80°C. Sagittal slices (30 m) were cut using a cryostat (Microm, HM505N), and all staining
procedures were performed as free ﬂoating. Following a 1-h blocking step at room temperature in PBS
supplemented with 1% bovine serum albumin (BSA), 0.2% Triton, and 10% goat serum, the sections were
incubated overnight at 4°C in primary antibody solutions containing 10% goat serum and 0.2% Triton in
PBS. The following antibodies were used: monoclonal humanized anti-CHIKV (CHK-166 and CHK-152 [66];
2 g/ml each), monoclonal human anti-RRV (RRV-1I9 [69] and/or RRV-86 [gift of J. Crowe, Vanderbilt
University]; 2 g/ml each), polyclonal rabbit antivimentin (Abcam, ab8978; dilution, 1:300), and poly-
clonal rabbit anti-sarcomeric -actinin (Abcam, ab137346; dilution, 1:100). Secondary anti-mouse Alexa
Fluor 555 and/or anti-rabbit Alexa Fluor 488 (Invitrogen) was incubated 1:500 in PBS for 2 h at room
temperature, and nuclei were visualized with DAPI (4=,6-diamidino-2-phenylindole). Slides were mounted
with Vectashield mounting medium (Vector Laboratories). Tissues were imaged on a Zeiss LSM880
confocal microscope at the Washington University Microscopy Core Facility. Image analysis and quan-
tiﬁcation of virus-infected SAA-positive or vimentin-positive cells were performed blinded to the inves-
tigator, using ImageJ software.
Viral RNA in situ hybridization. RNA in situ hybridization was performed using RNAscope 2.5
(Advanced Cell Diagnostics) according to the manufacturer’s instructions. PFA-ﬁxed, decalciﬁed, and
parafﬁn-embedded tissue sections were deparafﬁnized by incubating for 60 min at 60°C. Endogenous
peroxidases were quenched with H2O2 for 10 min at room temperature. Slides were boiled for 15 min in
RNAscope target retrieval reagents and incubated for 30 min in RNAscope Protease Plus before probe
hybridization. The probe targeting CHIKV RNA (479501) was designed and synthesized by Advanced Cell
Diagnostics. Tissues were counterstained with Gill’s hematoxylin and visualized using the Hamamatsu
NanoZoomer 2.0-HT system. Images were acquired on a Zeiss Axio Obesrver.D1 Wideﬁeld ﬂuorescence
microscope at the Washington University Microscopy Core Facility.
Statistical analysis. All data were analyzed using Prism software (GraphPad6, San Diego, CA).
Measurements of foot swelling were analyzed by 2-way analysis of variance (ANOVA) with Sidak’s
multiple comparison tests unless mentioned otherwise. Virological analyses of tissues, cytokine and
chemokine measurements, ﬂow cytometry data, and immunohistochemical quantiﬁcation all were
analyzed with the Mann-Whitney test.
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